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 55 
Despite great attention given to the recent Zika virus (ZIKV) epidemic in the Americas and its link 56 
to birth defects1,2, much remains unknown about ZIKV disease epidemiology and ZIKV evolution, 57 
in part due to a lack of genomic data. We applied multiple sequencing approaches to generate 110 58 
ZIKV genomes from clinical and mosquito samples from 10 countries and territories, greatly 59 
expanding the observed viral genetic diversity from this outbreak. We analyzed the timing and 60 
patterns of introductions into distinct geographic regions; our phylogenetic evidence suggests rapid 61 
expansion of the outbreak in Brazil and multiple introductions of outbreak strains into Puerto Rico, 62 
Honduras, Colombia, other Caribbean islands, and the continental US. We find that ZIKV 63 
circulated undetected in multiple regions for many months before the first locally transmitted cases 64 
were confirmed, highlighting the importance of viral surveillance. We identify mutations with 65 
possible functional implications for ZIKV biology and pathogenesis, as well as those potentially 66 
relevant to the effectiveness of diagnostic tests. 67 
 68 
Since its introduction into the Americas, mosquito-borne ZIKV (Family: Flaviviridae) has spread rapidly, 69 
causing hundreds of thousands of cases of ZIKV disease, as well as ZIKV congenital syndrome and likely 70 
other neurological complications1–3. Phylogenetic analysis of ZIKV can reveal the trajectory of the 71 
outbreak and detect mutations that may be associated with new disease phenotypes or affect molecular 72 
diagnostics. Despite the 70 years since its discovery and the scale of the recent outbreak, however, fewer 73 
than 100 ZIKV genomes have been sequenced directly from clinical samples. This is due in part to 74 
technical challenges posed by low viral loads (for example, often orders of magnitude lower than in Ebola 75 
virus or dengue virus infection4–6), and by loss of RNA integrity in samples collected and stored without 76 
sequencing in mind. Culturing the virus increases the material available for sequencing but can result in 77 
genetic variation that is not representative of the original clinical sample. 78 
 79 
We sought to gain a deeper understanding of the viral populations underpinning the ZIKV epidemic by 80 
extensive genome sequencing of the virus directly from samples collected as part of ongoing surveillance. 81 
We initially pursued unbiased metagenomic RNA sequencing to capture both ZIKV and other viruses 82 
known to be co-circulating with ZIKV5. In most of the 38 samples examined by this approach there 83 
proved to be insufficient ZIKV RNA for genome assembly, but it still proved valuable to verify results 84 
from other methods. Metagenomic data also revealed RNA from other viruses, including 41 likely novel 85 
viral sequence fragments in mosquito pools (Extended Data Table 1). In one patient we detected no 86 
ZIKV sequence but did assemble a complete genome from dengue virus (type 1), one of the viruses that 87 
co-circulates with and presents similarly to ZIKV7. 88 
 89 
To capture sufficient ZIKV content for genome assembly, we turned to two targeted approaches for 90 
enrichment before sequencing: multiplex PCR amplification8 and hybrid capture9. We sequenced and 91 
assembled complete or partial genomes from 110 samples from across the epidemic, out of 229 attempted 92 
(221 clinical samples from confirmed and possible ZIKV disease cases and eight mosquito pools; Table 93 
1, Supplementary Table 1). This dataset, which we used for further analysis, includes 110 genomes 94 
produced using multiplex PCR amplification (amplicon sequencing) and a subset of 37 genomes 95 
produced using hybrid capture (out of 66 attempted). Because these approaches amplify any contaminant 96 
ZIKV content, we relied heavily on negative controls to detect artefactual sequence, and we established 97 
stringent, method-specific thresholds on coverage and completeness for calling high confidence ZIKV 98 
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assemblies (Fig. 1a). Completeness and coverage for these genomes are shown in Fig. 1b and c; the 99 
median fraction of the genome with unambiguous base calls was 93%. Per-base discordance between 100 
genomes produced by the two methods was 0.017% across the genome, 0.15% at polymorphic positions, 101 
and 2.2% for minor allele base calls. Concordance of within-sample variants is shown in more detail in 102 
Fig. 1d-f. Patient sample type (urine, serum, or plasma) made no significant difference in sequencing 103 
success in our study (Extended Data Fig. 1). 104 
 105 
To investigate the spread of ZIKV in the Americas we performed a phylogenetic analysis of the 110 106 
genomes from our dataset, together with 64 published genomes available on NCBI GenBank and in our 107 
companion papers10,11 (Fig. 2a). Our reconstructed phylogeny (Fig. 2b), which is based on a molecular 108 
clock (Extended Data Fig. 2), is consistent with the outbreak originating in Brazil12: Brazil ZIKV 109 
genomes appear on all deep branches of the tree, and their most recent common ancestor is the root of the 110 
entire tree. We estimate the date of that common ancestor to have been in early 2014 (95% credible 111 
interval, CI, August 2013 to July 2014). The shape of the tree near the root remains uncertain (i.e. the 112 
nodes have low posterior probabilities) because there are too few mutations to clearly distinguish the 113 
branches. This pattern suggests rapid early spread of the outbreak, consistent with the introduction of a 114 
new virus to an immunologically naive population. ZIKV genomes from Colombia (n=10), Honduras 115 
(n=18), and Puerto Rico (n=3) cluster within distinct, well-supported clades. We also observed a clade 116 
consisting entirely of genomes from patients who contracted ZIKV in one of three Caribbean countries 117 
(the Dominican Republic, Jamaica, and Haiti) or the continental US, containing 30 of 32 genomes from 118 
the Dominican Republic and 19 of 20 from the continental US. We estimated the within-outbreak 119 
substitution rate to be 1.15x10-3 substitutions/site/year (95% CI [9.78x10-4, 1.33x10-3]), similar to prior 120 
estimates for this outbreak12. This is somewhat higher (1.3x–5x) than reported rates for other 121 
flaviviruses13, but is measured over a short sampling period, and therefore may include a higher 122 
proportion of mildly deleterious mutations that have not yet been removed through purifying selection.  123 
 124 
Determining when ZIKV arrived in specific regions helps elucidate the spread of the outbreak and track 125 
rising incidence of possible complications of ZIKV infection. The majority of the ZIKV genomes from 126 
our study fall into four major clades from different geographic regions, for which we estimated a likely 127 
date for ZIKV arrival. In each case, the date was months earlier than the first confirmed, locally 128 
transmitted case, indicating ongoing local circulation of ZIKV before its detection. In Puerto Rico, the 129 
estimated date was 4.5 months earlier than the first confirmed local case14; it was 8 months earlier in 130 
Honduras15, 5.5 months earlier in Colombia16, and 9 months earlier for the Caribbean/continental US 131 
clade17. In each case, the arrival date represents the estimated time to the most recent common ancestor 132 
(tMRCA) for the corresponding clade in our phylogeny (Fig. 2c). See Extended Data Fig. 3 and 133 
Extended Data Table 2 for details. Similar temporal gaps between the tMRCA of local transmission 134 
chains and the earliest detected cases were seen when chikungunya virus emerged in the Americas18. We 135 
also observed evidence for several introductions of ZIKV into the continental US, and found that 136 
sequences from mosquito and human samples collected in Florida cluster together, consistent with the 137 
finding of local ZIKV transmission in Florida in a companion paper11.  138 
 139 
Principal component analysis (PCA) is consistent with the phylogenetic observations (Fig. 2d). It shows 140 
tight clustering among ZIKV genomes from the continental US, the Dominican Republic, and Jamaica. 141 
ZIKV genomes from Brazil and Colombia are similar and distinct from genomes sampled in other 142 
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countries. ZIKV genomes from Honduras form a third cluster that also contains genomes from Guatemala 143 
or El Salvador. The PCA results show no clear stratification of ZIKV within Brazil. 144 
 145 
Genetic variation can provide important clues to understanding ZIKV biology and pathogenesis and can 146 
reveal potentially functional changes in the virus. We observed 1030 single nucleotide polymorphisms 147 
(SNPs) in the complete dataset, well distributed across the genome (Fig. 3a). Any effect of these 148 
mutations cannot be determined from these data; however, the most likely candidates for functional 149 
mutations would be among the 202 nonsynonymous SNPs (Supplementary Table 2) and the 32 SNPs in 150 
the 5’ and 3’ untranslated regions (UTRs). Adaptive mutations are more likely to be found at high 151 
frequency or to be seen multiple times, although both effects can also occur by chance. We observed five 152 
positions with nonsynonymous mutations at >5% minor allele frequency that occur on two or more 153 
branches of the tree (Fig. 3b); two of these (at 4287 and 8991) occur together and might represent 154 
incorrect placement of a Brazil branch in the tree. The remaining three are more likely to represent 155 
multiple nonsynonymous mutations; one (at 9240) appears to involve nonsynonymous mutations to two 156 
different alleles. 157 
 158 
To assess the possible biological significance of these mutations, we looked for evidence of selection in 159 
the ZIKV genome. Viral surface glycoproteins are known targets of positive selection, and mutations in 160 
these proteins can confer adaptation to new vectors19 or aid immune escape20,21. We therefore searched for 161 
an excess of nonsynonymous mutations in the ZIKV envelope glycoprotein (E). However, the 162 
nonsynonymous substitution rate in E proved to be similar to that in the rest of the coding region (Fig. 3c, 163 
left); moreover, amino acid changes were significantly more conservative in that region than elsewhere 164 
(Fig. 3c, middle and right). Any diversifying selection occurring in the surface protein thus appears to be 165 
operating under selective constraint. We also found evidence for purifying selection in the ZIKV 3’ UTR 166 
(Fig. 3d, Supplementary Table 3), a region important for viral replication22. 167 
 168 
While the transition-to-transversion ratio (6.98) was within the range seen in other viruses23, we observed 169 
a significantly higher frequency of C-to-T and T-to-C substitutions than other transitions (Fig. 3d, 170 
Extended Data Fig. 4, Supplementary Table 3). This enrichment is apparent both in the genome as a 171 
whole and at 4-fold degenerate sites, where selection pressure is minimal. Many processes may contribute 172 
to this conspicuous mutation pattern, including mutational bias of the ZIKV RNA-dependent RNA 173 
polymerase, host RNA editing enzymes (e.g. APOBECs, ADARs) acting upon viral RNA, and chemical 174 
deamination, but further investigation is required to determine the cause of this phenomenon. 175 
 176 
Mismatches between PCR assays and viral sequence are a potential source of poor diagnostic 177 
performance in this outbreak24. To assess the potential impact of ongoing viral evolution on diagnostic 178 
function, we compared eight published qRT-PCR-based primer/probe sets to our data. We found 179 
numerous sites where the probe or primer did not match an allele found among the 174 ZIKV genomes 180 
from the current dataset (Fig. 3e). In most cases, the discordant allele was shared by all outbreak samples, 181 
presumably because it was present in the Asian lineage that entered the Americas. These mismatches 182 
could affect all uses of the diagnostic assay in the outbreak. We also found mismatches from new 183 
mutations that occurred following ZIKV entry into the Americas. Most of these were present in less than 184 
10% of samples, although one was seen in 29%. These observations suggest that genome evolution has 185 
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not caused widespread degradation of diagnostic performance during the course of the outbreak, but that 186 
mutations continue to accumulate and ongoing monitoring is needed.   187 
 188 
Analysis of within-host viral genetic diversity can reveal important information for understanding virus-189 
host interactions and viral transmission. However, accurately identifying these variants in low-titer 190 
clinical samples is challenging, and further complicated by potential artefacts associated with enrichment 191 
prior to sequencing. To investigate whether we could reliably detect within-host ZIKV variants in our 192 
data, we identified within-host variants in a cultured ZIKV isolate used as a positive control throughout 193 
our study, and found that both amplicon sequencing and hybrid capture data produced concordant and 194 
replicable variant calls (Fig. 1d). In clinical samples, hybrid capture within-host variants were noisier but 195 
contained a reliable subset: although most variants were not validated by the other sequencing method or 196 
by a technical replicate, those at high frequency were always replicable, as were those that passed a 197 
previously described filter25 (Fig. 1e-f, Extended Data Table 3). Within this high confidence set we 198 
looked for variants shared between samples as a clue to transmission patterns, but there were too few 199 
variants to draw any meaningful conclusions. By contrast, within-host variants identified in amplicon 200 
sequencing data were unreliable at all frequencies (Fig. 1f, Extended Data Table 3), suggesting that 201 
further technical development is needed before amplicon sequencing can be used to study within-host 202 
variation in ZIKV and other clinical samples with low viral titer. 203 
 204 
Sequencing low titer viruses like ZIKV directly from clinical samples presents several challenges that 205 
have likely contributed to the paucity of genomes available from the current outbreak. While development 206 
of technical and analytical methods will surely continue, we note that factors upstream in the process, 207 
including collection site and cohort, were strong predictors of sequencing success in our study (Extended 208 
Data Fig. 1). This highlights the importance of continuing development and implementation of best 209 
practices for sample handling, without disrupting standard clinical workflows, for wider adoption of 210 
genome surveillance during outbreaks. Additional sequencing, however challenging, remains critical to 211 
ongoing investigation of ZIKV biology and pathogenesis. Together with two companion studies10,11, this 212 
effort advances both technological and collaborative strategies for genome surveillance in the face of 213 
unexpected outbreak challenges. 214 
  215 
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Figures 255 
 256 
Country or territory Samples 
Samples with 
metagenomic 
data 
Amplicon 
sequencing 
genomes 
Hybrid 
capture 
genomes 
Total 
genomes 
Brazil 53 12 27 7 27 
Colombia 20 0 4 2 4 
Dominican Republic 45 7 30 9 30 
Guatemala/El Salvador 3 0 1 0 1 
Haiti 4 0 1 0 1 
Honduras 20 6 18 8 18 
Jamaica 20 0 5 0 5 
Martinique 3 0 1 0 1 
Puerto Rico 15 0 3 1 3 
Continental US 36 12 20 10 20 
Other 10 1 0 0 0 
Total 229 38 110 37 110 
 257 
Table 1 | Samples and genomes by region. Sample source information and sequencing results for 229 clinical and 258 
mosquito pool samples. Continental US includes 8 mosquito pool samples; all others are clinical samples. In the final 259 
column, genomes generated by both methods are counted only once. “Other” includes regions without a ZIKV 260 
genome included in downstream analysis. 261 
 262 
 263 
Figure 1 | Sequence data from clinical and mosquito samples. (a) Thresholds used to select samples for 264 
downstream analysis. Each point is a replicate. Red and blue shading: regions of accepted amplicon sequencing and 265 
hybrid capture genome assemblies, respectively. Not shown: hybrid capture positive controls with depth >10,000x. 266 
(b) Amplicon sequencing coverage by sample (row) across the ZIKV genome. Red: sequencing depth ≥100x; 267 
heatmap (bottom) sums coverage across all samples. White horizontal lines: amplicon locations. (c) Relative 268 
sequencing depth across hybrid capture genomes. (d) Within-sample variants for a single cultured isolate (PE243) 269 
across seven technical replicates. Each point is a variant in a replicate identified using amplicon sequencing (red) or 270 
hybrid capture (blue). Variants are plotted if the pooled frequency across replicates by either method is ≥1%. (e) 271 
Within-sample variant frequencies across methods. Each point is a variant in an individual sample and points are 272 
plotted on a log-log scale. Green points: “verified” variants detected by hybrid capture that pass strand bias and 273 
frequency filters. (f) Counts of within-sample variants across two replicate libraries, for each method. Variants are 274 
plotted in the frequency bin corresponding to the higher of the two detected frequencies. In (e-f), frequencies <1% are 275 
shown at 0%. 276 
 277 
 278 
Figure 2 | Zika virus spread throughout the Americas. (a) Samples were collected in each of the colored 279 
countries/territories. Specific state, department, or province of origin for samples in this study are highlighted if 280 
known. (b) Maximum clade credibility tree. Dotted tips: genomes generated in this study. Node labels are posterior 281 
probabilities indicating support for the node. Violin plots denote probability distributions for the tMRCA of four 282 
highlighted clades. (c) Time elapsed between estimated tMRCA and date of first confirmed, locally transmitted case. 283 
Color: distributions based on relaxed clock model (also shown in (b)); grey: strict clock. “Caribbean” includes the 284 
continental US. (d) Principal component analysis of variants. Circles: data generated in this study; diamonds: other 285 
publicly available genomes from this outbreak. Percentage of variance explained by each component is indicated on 286 
axis. 287 
 288 
 289 
Figure 3 | Geographic and genomic distribution of Zika virus variation. (a) Location of variants in the ZIKV 290 
genome. The minor allele frequency is the proportion of the 174 genomes from this outbreak that share a variant. 291 
Dotted bars: <25% of samples had a base call at that position. (b) Phylogenetic distribution of nonsynonymous 292 
variants with minor allele frequency ≥5%, shown on the branch where the mutation most likely occurred. Grey outline: 293 
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variant might be on next-most ancestral branch (in two cases, 2 branches upstream), but exact location is unclear 294 
because of missing data. Red circles: variants occurring at more than one location in the tree. (c) Conservation of the 295 
ZIKV envelope (E) region. Left: nonsynonymous variants per amino acid for the E region (dark grey) and the rest of 296 
the coding region (light grey). Middle: proportion of nonsynonymous variants resulting in negative BLOSUM62 scores, 297 
which indicate unlikely or extreme substitutions (p < 0.039, χ2 test). Right: average of BLOSUM62 scores for 298 
nonsynonymous variants (p < 0.037, 2-sample t-test). (d) Constraint in the ZIKV 3’ UTR and observed transition rates 299 
over the ZIKV genome. (e) ZIKV diversity in diagnostic primer and probe regions. Top: locations of published probes 300 
(dark blue) and primers (cyan)26–31 on the ZIKV genome. Bottom: each column represents a nucleotide position in the 301 
probe or primer. Colors in the column indicate the fraction of ZIKV genomes (out of 174) that match the probe/primer 302 
sequence (grey), differ from it (red), or have no data for that position (white).  303 
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Methods 304 
 305 
Ethics statement 306 
The clinical studies from which samples were obtained were evaluated and approved by relevant Institutional 307 
Review Boards/Ethics Review Committees at: Hospital General de la Plaza de la Salud (Santo Domingo, Dominican 308 
Republic), University of the West Indies (Kingston, Jamaica), Universidad Nacional Autónoma de Honduras 309 
(Tegucigalpa, Honduras), Oswaldo Cruz Foundation (Rio de Janeiro, Brazil), Centro de Investigaciones 310 
Epidemiologicas - Universidad Industrial de Santander (Bucaramanga, Colombia), Massachusetts Department of 311 
Public Health (Jamaica Plain, Massachusetts), and Florida Department of Health (Tallahassee, Florida). Informed 312 
consent was obtained from all participants enrolled in studies at Hospital General de la Plaza de la Salud, 313 
Universidad Nacional Autónoma de Honduras, Oswaldo Cruz Foundation, and Universidad Industrial de Santander. 314 
IRBs at the University of West Indies, Massachusetts Department of Public Health, and Florida Department of 315 
Health granted waivers of consent given this research with leftover clinical diagnostic samples involved no more 316 
than minimal risk. Harvard University and Massachusetts Institute of Technology (MIT) Institutional Review 317 
Boards/Ethics Review Committees provided approval for sequencing and secondary analysis of samples collected 318 
by the aforementioned institutions. 319 
 320 
Sample collections and study subjects 321 
Suspected ZIKV cases (including high-risk travelers) were enrolled through study protocols at multiple 322 
aforementioned collection sites. Clinical samples (including blood, urine, cerebrospinal fluid, and saliva) were 323 
obtained from suspected or confirmed ZIKV cases and from high-risk travelers. De-identified information about 324 
study participants and other sample metadata are reported in Supplementary Table 1. 325 
 326 
Viral RNA isolation 327 
RNA was isolated following manufacturer's standard operating protocol for 0.14 mL up to 1 mL samples32 using the 328 
QIAamp Viral RNA Minikit (Qiagen), except that in some cases 0.1 M final concentration of β-mercaptoethanol (as 329 
a reducing agent) or 40 μg/mL final concentration of linear acrylamide (Ambion) (as a carrier) were added to AVL 330 
buffer prior to inactivation. Extracted RNA was resuspended in AVE buffer or nuclease-free water. In some cases, 331 
viral samples were concentrated using Vivaspin-500 centrifugal concentrators (Sigma-Aldrich) prior to inactivation 332 
and extraction. In these cases, 0.84 mL of sample was concentrated to 0.14 mL by passing through a 30 kDa filter 333 
and discarding the flow through. 334 
 335 
Carrier RNA and host rRNA depletion 336 
In a subset of human samples, carrier poly(rA) RNA and host rRNA were depleted from RNA samples using RNase 337 
H selective depletion9,33. Briefly, oligo d(T) (40 nt long) and/or DNA probes complementary to human rRNA were 338 
hybridized to the sample RNA. The sample was then treated with 15 units of Hybridase Thermostable RNase H 339 
(Epicentre) for 30 minutes at 45°C. The complementary DNA probes were removed by treating each reaction with 340 
an RNase-free DNase (Qiagen) according to the manufacturer’s protocol. Following depletion, samples were 341 
purified using 1.8x volume AMPure RNAclean beads (Beckman Coulter Genomics) and eluted into 10 µl water for 342 
cDNA synthesis. 343 
 344 
Illumina library construction and sequencing 345 
cDNA synthesis was performed as described in previously published RNA-seq methods9. To track potential cross-346 
contamination, 50 fg of synthetic RNA (gift from M. Salit, NIST) was spiked into samples using unique RNA for 347 
each individual ZIKV sample. ZIKV negative control cDNA libraries were prepared from water, human K-562 total 348 
RNA (Ambion), or EBOV (KY425633.1) seed stock; ZIKV positive controls were prepared from ZIKV Senegal 349 
(isolate HD78788) or ZIKV Pernambuco (isolate PE243; KX197192.1) seed stock. The dual index Accel-NGS® 2S 350 
Plus DNA Library Kit (Swift Biosciences) was used for library preparation. Approximately half of the cDNA 351 
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product was used for library construction, and indexed libraries were generated using 18 cycles of PCR. Each 352 
individual sample was indexed with a unique barcode. Libraries were pooled at equal molarity and sequenced on the 353 
Illumina HiSeq 2500 or MiSeq (paired-end reads) platforms. 354 
 355 
Amplicon-based cDNA synthesis and library construction 356 
ZIKV amplicons were prepared as described8,11, similarly to “RNA jackhammering” for preparing low input viral 357 
samples for sequencing34, with slight modifications. After PCR amplification, each amplicon pool was quantified on 358 
a 2200 Tapestation (Agilent Technologies) using High Sensitivity D1000 ScreenTape (Agilent Technologies). 2 µL 359 
of a 1:10 dilution of the amplicon cDNA was loaded and the concentration of the 350-550 bp fragments was 360 
calculated. The cDNA concentration, as reported by the Tapestation, was highly predictive of sequencing outcome 361 
(i.e. whether a sample passes genome assembly thresholds) (Extended Data Fig. 5). cDNA from each of the two 362 
amplicon pools were mixed equally (10-25 ng each) and libraries were prepared using the dual index Accel-NGS® 363 
2S Plus DNA Library Kit (Swift Biosciences) according to manufacturer's protocol. Libraries were indexed with a 364 
unique barcode using 7 cycles of PCR, pooled equally and sequenced on the Illumina MiSeq (250 bp paired-end 365 
reads) platform. Primer sequences were removed by hard trimming the first 30 bases for each insert read prior to 366 
analysis. 367 
 368 
Zika virus hybrid capture 369 
Viral hybrid capture was performed as previously described9. Probes were created to target ZIKV and chikungunya 370 
virus (CHIKV). Candidate probes were created by tiling across publicly available sequences for ZIKV and CHIKV 371 
on NCBI GenBank35. Probes were selected from among these candidate probes to minimize the number used while 372 
maintaining coverage of the observed diversity of the viruses. Alternating universal adapters were added to allow 373 
two separate PCR amplifications, each consisting of non-overlapping probes. (To download probe sequences, see 374 
Supplementary Information.) 375 
 376 
The probes were synthesized on a 12k array (CustomArray). The synthesized oligos were amplified by two separate 377 
emulsion PCR reactions with primers containing T7 RNA polymerase promoter. Biotinylated baits were in vitro 378 
transcribed (MEGAshortscript, Ambion) and added to prepared ZIKV libraries. The baits and libraries were 379 
hybridized overnight (~16 hrs), captured on streptavidin beads, washed, and re-amplified by PCR using the Illumina 380 
adapter sequences. Capture libraries were then pooled and sequenced. In some cases, a second round of hybrid 381 
capture was performed on PCR-amplified capture libraries to further enrich the ZIKV content of sequencing 382 
libraries (Extended Data Fig. 6). In the main text, “hybrid capture” refers to a combination of hybrid capture 383 
sequencing data and data from the same libraries without capture (unbiased), unless explicitly distinguished. 384 
 385 
Genome assembly 386 
We assembled reads from all sequencing methods into genomes using viral-ngs v1.13.336,37. We taxonomically 387 
filtered reads from amplicon sequencing against a ZIKV reference, KU321639.1. We filtered reads from other 388 
approaches against the list of accessions provided in Supplementary Information. To compute results on individual 389 
replicates, we de novo assembled these and scaffolded against KU321639.1. To obtain final genomes for analysis, 390 
we pooled data from multiple replicates of a sample, de novo assembled, and scaffolded against KX197192.1. For 391 
all assemblies, we set the viral-ngs ‘assembly_min_length_fraction_of_reference’ and ‘assembly_min_unambig’ 392 
parameters to 0.01. For amplicon sequencing data, unambiguous base calls required at least 90% of reads to agree in 393 
order to call that allele (‘major_cutoff’ = 0.9); for hybrid capture data, we used the default threshold of 50%. We 394 
modified viral-ngs so that calls to GATK’s UnifiedGenotyper set ‘min_indel_count_for_genotyping’ to 2. 395 
 396 
At 3 sites with insertions or deletions (indels) in the consensus genome CDS, we corrected the genome using Sanger 397 
sequencing of the RT-PCR product (namely, at 3447 in the genome for sample DOM_2016_BB-0085-SER; at 5469 398 
in BRA_2016_FC-DQ12D1-PLA; and at 6516-6564 in BRA_2016_FC-DQ107D1-URI, with coordinates in 399 
KX197192.1). At other indels in the consensus genome CDS, we replaced the indel with ambiguity. 400 
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 401 
Depth of coverage values from amplicon sequencing include read duplicates. In all other cases, we removed 402 
duplicates with viral-ngs. 403 
 404 
Identification of non-ZIKV viruses in samples by unbiased sequencing 405 
Using Kraken v0.10.638 in viral-ngs, we built a database that includes its default “full” database (which incorporates 406 
all bacterial and viral whole genomes from RefSeq39 as of October 2015). Additionally, we included the whole 407 
human genome (hg38), genomes from PlasmoDB40, sequences covering mosquito genomes (Aedes aegypti, Aedes 408 
albopictus, Anopheles albimanus, Anopheles quadrimaculatus, Culex quinquefasciatus, and the outgroup 409 
Drosophila melanogaster) from GenBank35, protozoa and fungi whole genomes from RefSeq, SILVA LTP 16s 410 
rRNA sequences41, and all sequences from NCBI’s viral accession list42 (as of October 2015) for viral taxa that have 411 
human as a host. (To download database, see Supplementary Information.) 412 
 413 
For each sample, we ran Kraken on data from unbiased sequencing replicates (not including hybrid capture data) 414 
and searched its output reports for viral taxa with more than 100 reported reads. We manually filtered the results, 415 
removing ZIKV, bacteriophages, and known lab contaminants. For each sample and its associated taxa, we 416 
assembled genomes using viral-ngs as described above; results are in Extended Data Table 1a. We used the 417 
following genomes for taxonomically filtering reads and as the reference for assembly: KJ741267.1 (cell fusing 418 
agent virus), AY292384.1 (deformed wing virus), NC_001477.1 (dengue virus type 1), LC164349.1 (JC 419 
polyomavirus). When reporting sequence identity of an assembly to its taxon, we used BLASTN43 to determine the 420 
identity between the sequence and the reference used for its assembly. 421 
 422 
To focus on metagenomics of mosquito pools (Extended Data Table 1b), we considered unbiased sequencing data 423 
from 8 mosquito pools (not including hybrid capture data). We first ran the depletion pipeline of viral-ngs on raw 424 
data and then ran the viral-ngs Trinity44 assembly pipeline on the depleted reads to assemble them into contigs. We 425 
pooled contigs from all mosquito pool samples and identified all duplicate contigs with sequence identity >95% 426 
using CD-HIT45. Additionally, we used predicted coding sequences from Prodigal 2.6.346 to identify duplicate 427 
protein sequences at >95% identity. We classified contigs using BLASTN43 against nt and BLASTX43 against nr (as 428 
of February 2017) and discarded all contigs with an e-value greater than 1E-4. We define viral contigs as contigs 429 
that hit a viral sequence, and we manually removed all reverse-transcriptase-like contigs due to their similarity to 430 
retrotransposon elements within the Aedes aegypti genome. We categorized viral contigs with less than 80% amino 431 
acid identity to their best hit as likely novel viral contigs. Supplementary Table 4 lists the unique viral contigs we 432 
found, their best hit, and information scoring the hit. 433 
 434 
Relationship between metadata and sequencing outcome 435 
To determine if available sample metadata are predictive of sequencing outcome, we tested the following variables: 436 
sample collection site, patient gender, patient age, sample type, and the number of days between symptom onset and 437 
sample collection (“collection interval”). To describe sequencing outcome of a sample S, we used the following 438 
response variable YS: 439 
        mean({ I(R) * (number of unambiguous bases in R) for all amplicon sequencing replicates R of S }), 440 
            where I(R)=1 if median depth of coverage of R ≥275 and I(R)=0 otherwise 441 
This value is listed in Supplementary Table 1 under “Dependent variable used in regression on metadata”. We 442 
excluded the saliva, cerebrospinal fluid, and whole blood sample types due to sample number (n=1), and also 443 
excluded mosquito pool samples and rows with missing values. We excluded samples from one collection site 444 
(prefix “JAM_2016_WI-”) because most had missing values. We treated samples with type “Plasma EDTA” as 445 
having type “Plasma”. We treated the “collection interval” variable as categorical (0-1, 2-3, 4-6, and 7+ days). 446 
 447 
With a single model we underfit the zero counts, possibly because many zeros (samples without a replicate that 448 
passes ZIKV assembly) are truly ZIKV-negative. We thus view the data as coming from two processes: one 449 
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determining whether a sample is ZIKV-positive or ZIKV-negative, and another that determines, among the observed 450 
passing samples, how much of a ZIKV genome we are able to sequence. We modeled the first process, predicting 451 
whether a sample is passing, with logistic regression (in R using GLM47 with binomial family and logit link); here, 452 
the observed passing samples are the samples S for which YS ≥ 2500. For the second, we performed a beta 453 
regression, using only the observed passing samples, of YS divided by ZIKV genome length on the predictor 454 
variables. We implemented this in R using the betareg package48 and transformed fractions from the closed unit 455 
interval to the open unit interval as the authors suggest. 456 
 457 
To test the significance of predictor variables, we used a likelihood ratio test. For variable Xi we compared a full 458 
model (with all predictors) against a model that uses all predictors except Xi. Results of these tests are shown in 459 
Extended Data Fig. 1a and d. We explore the effects of sample type and collection interval on obtaining a passing 460 
assembly in Extended Data Fig. 1b and c, respectively. Error bars are 95% confidence intervals derived from 461 
binomial distributions. We explore the effects of these same two variables on YS (in passing samples only) in 462 
Extended Data Fig. 1e and f. 463 
 464 
Criteria for pooling across replicates 465 
We attempted to sequence one or more replicates of each sample and attempted to assemble a genome from each 466 
replicate. We discarded data from any replicates whose assembly showed high sequence similarity, in any part of the 467 
genome, to our assembly of the genome in a sample consisting of an African (Senegal) lineage (strain HD78788) of 468 
ZIKV. We used this sample as a positive control throughout this study, and considered its presence in the assembly 469 
of a clinical or mosquito pool sample to be evidence of contamination. Similarly, we discarded data from four 470 
replicates belonging to samples from the Dominican Republic because they yielded assemblies that were 471 
unexpectedly identical or highly similar to our assembly of the ZIKV isolate PE243 genome, another positive 472 
control used in this study. We also discarded data from replicates that showed evidence of contamination, at the 473 
RNA stage, by the baits used in hybrid capture; we detected these by looking for adapters that were added to these 474 
probes for amplification. 475 
 476 
For amplicon sequencing, we consider an assembly of a replicate to be “passing” if it contains at least 2500 477 
unambiguous base calls and has a median depth of coverage of at least 275x over its unambiguous bases (depth 478 
includes duplicate reads). For the unbiased and hybrid capture approaches, we consider an assembly of a replicate 479 
“passing” if it contains at least 4000 unambiguous base calls. For each approach, the unambiguous base threshold is 480 
based on an observed density of negative controls below the threshold (Fig. 1a). For amplicon sequencing 481 
assemblies, we added a coverage depth threshold because coverage depth was roughly binary across replicates, with 482 
negative controls falling in the lower class. Based on these thresholds, 0 of 99 negative controls used throughout our 483 
sequencing runs yield passing assemblies and 32 of 32 positive controls yield passing assemblies. 484 
 485 
We consider a sample to have a passing assembly if any of its replicates, by either method, yields an assembly that 486 
passes the above thresholds. For each sample with at least one passing assembly, we pooled read data across 487 
replicates for each sample, including replicates with assemblies that do not pass the assembly thresholds. When data 488 
was available from both amplicon sequencing and unbiased/hybrid capture approaches, we pooled amplicon 489 
sequencing data separately from data produced by the unbiased and hybrid capture approaches, the latter two of 490 
which were pooled together (henceforth, the “hybrid capture” pool). We then assembled a genome from each set of 491 
pooled data. When assemblies on pooled data were available from both approaches, we selected for downstream 492 
analysis the assembly from the hybrid capture approach if it had more than 10267 unambiguous base calls (95% of 493 
the reference genome used, GenBank accession KX197192.1); when this condition was not met, we selected the one 494 
that had more unambiguous base calls. 495 
 496 
The number of ZIKV genomes publicly available prior to this study is the result of an NCBI GenBank35 search for 497 
ZIKV in February 2017. We filtered any sequences with length <4000 nt, excluded sequences that are being 498 
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published as part of this study or a companion paper10,11, excluded sequences from non-human hosts, and excluded 499 
sequences labeled as having been passaged. We counted fewer than 100 sequences, the precise number depending 500 
on details of the count. 501 
 502 
Visualization of coverage depth across genomes 503 
For amplicon sequencing data, we plotted coverage across the 110 samples that yielded a passing assembly by 504 
amplicon sequencing (Fig. 1b). With viral-ngs, we aligned depleted reads to the reference sequence KX197192.1 505 
using the novoalign aligner with options ‘-r Random -l 40 -g 40 -x 20 -t 100 -k’. Because of the nature of amplicon 506 
sequencing, duplicates were not identified or removed. We binarized depth at each nucleotide position, showing red 507 
if depth of coverage is at least 100x. Rows (samples) are hierarchically clustered to ease visualization. 508 
 509 
For hybrid capture sequencing data, we plotted depth of coverage across the 37 samples that yielded a passing 510 
assembly (Fig. 1c). We aligned reads as described above for amplicon sequencing data, except we removed 511 
duplicates. For each sample, we calculated depth of coverage at each nucleotide position.  We then scaled the values 512 
for each sample so that each would have a mean depth of 1.0. At each nucleotide position, we calculated the median 513 
depth across the samples, as well as the 20th and 80th percentiles. We plotted the mean of each of these metrics 514 
within a 200 nt sliding window. 515 
 516 
Multiple sequence alignments 517 
We aligned ZIKV consensus genomes using MAFFT v7.22149 with the following parameters: ‘--maxiterate 1000 --518 
ep 0.123 --localpair’. 519 
 520 
In Supplementary Data, we provide sequences and alignments used in analyses. 521 
 522 
Analysis of within- and between-sample variants 523 
To measure overall per-base discordance between consensus genomes produced by amplicon sequencing and hybrid 524 
capture, we considered all sites where base calls were made in both the amplicon sequencing and hybrid capture 525 
consensus genomes of a sample, and we calculated the fraction in which the bases were not in agreement. To 526 
measure discordance at polymorphic sites, we took all of the consensus genomes generated in this study that we 527 
selected for downstream analysis and searched for positions with polymorphism (see Criteria for pooling across 528 
replicates for choosing among the amplicon sequencing and hybrid capture genome when both are available). We 529 
then looked at these positions in genomes that were available from both methods, and we calculated the fraction in 530 
which the alleles were not in agreement.  531 
 532 
To measure discordance at minor alleles, we took all of the consensus genomes generated in this study that we 533 
selected for downstream analysis and searched for minor alleles. We then looked at all sites at which there was a 534 
minor allele and for which genomes from both methods were available, and we calculated the fraction in which the 535 
alleles were not in agreement. For these calculations, we tolerated partial ambiguity (e.g. ‘Y’ is concordant with 536 
‘T’). If one genome had full ambiguity (‘N’) at a position and the other genome had an indel, we counted the site as 537 
discordant; otherwise, if one genome had full ambiguity, we did not count the site. 538 
 539 
After assembling genomes, we determined within-sample allele frequencies for each sample by running V-Phaser 540 
2.0 via viral-ngs37 on all pooled reads mapping to the sample assembly. When determining per-library allele counts 541 
at each variant position, we modified viral-ngs to require a minimum base (Phred) quality score of 30 for all bases, 542 
discard anomalous read pairs, and use per-base alignment quality (BAQ) in its calls to SAMtools50 mpileup. This is 543 
particularly helpful for filtering spurious amplicon sequencing variants because all generated reads start and end at a 544 
limited number of positions (due to the pre-determined tiling of amplicons across the genome). Because amplicon 545 
sequencing libraries were sequenced using 250 bp paired-end reads, bases near the middle of the ~450 nt amplicons 546 
fall at the end of both paired reads, where quality scores drop and incorrect base calls are more likely. To determine 547 
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the overall frequency of each variant in a sample, we summed allele counts (calculated using SAMtools50 mpileup 548 
via viral-ngs) across libraries. 549 
 550 
When comparing variant frequencies between amplicon sequencing (7 technical replicates) and hybrid capture (7 551 
technical replicates) replicates of the PE243 positive control (Fig. 1d), we include only positions at which the mean 552 
(pooled) frequency across replicates within at least one method was ≥1%. When comparing allele frequencies 553 
between replicate libraries, we restricted the sample set to only samples with a passing assembly in both methods, 554 
and included only samples with two or more replicates. In contrast, when comparing alleles across methods we 555 
included samples that have a passing assembly by either method, with any number of replicates. For these 556 
comparisons, we only included positions with a minor variant; i.e. positions for which both libraries/methods had an 557 
allele at 100% were removed, even if the single allele differed between the two libraries/methods. Additionally, we 558 
considered any allele with frequency <1% as not found (0%). 559 
  560 
When comparing allele frequencies across methods: let fa and fhc be frequencies in amplicon sequencing and hybrid 561 
capture, respectively. If both are non-zero, we only included an allele if the read depth at its position was ≥1/min(fa, 562 
fhc) in both methods, and if depth at the position was at least 100 for hybrid capture and 275 for amplicon 563 
sequencing. If fa=0, we required a read depth of max(1/fhc, 275) at the position in the amplicon sequencing method; 564 
similarly, if fhc=0 we required a read depth of max(1/fa, 100) at the position in the hybrid capture method. This was 565 
to eliminate lack of coverage as a reason for discrepancy between two methods. When comparing allele frequencies 566 
across sequencing replicates within a method, we imposed only a minimum read depth (275x for amplicon 567 
sequencing and 100x for hybrid capture), but required this depth in both libraries. In samples with more than two 568 
replicates, we only considered the two replicates with the highest depth at each plotted position. 569 
 570 
We considered allele frequencies from hybrid capture sequencing “verified” if they passed the strand bias and 571 
frequency filters described in Gire et al. 201425, with the exception that we imposed a minimum allele frequency of 572 
1% and allowed a variant identified in only one library if its frequency was ≥5%. In Extended Data Table 3 and 573 
Fig. 1f, we considered variants “validated” if they were present at ≥1% frequency in both libraries or methods. 574 
When comparing two libraries for a given method M (amplicon sequencing or hybrid capture): the proportion 575 
unvalidated is the fraction, among all variants in M at ≥1% frequency in at least one library, of the variants that are 576 
at ≥1% frequency in exactly one of the two libraries. Similarly, when comparing methods: the proportion 577 
unvalidated for a method M is the fraction, among all variants at ≥1% frequency in M, of the variants that are at ≥1% 578 
frequency in M and <1% frequency in the other method. 579 
 580 
We initially called SNPs on the aligned consensus genomes using Geneious version 9.1.751. We converted all fully 581 
or partially ambiguous calls, which are treated by Geneious as variants, into missing data. We then removed all sites 582 
that were no longer polymorphic from the SNP set and re-calculated allele frequencies. A nonsynonymous SNP is 583 
shown on the tree (Fig. 3b) if it includes an allele that is nonsynonymous relative to the ancestral state (see 584 
Molecular clock phylogenetics and ancestral state reconstruction section below) and has a minor allele 585 
frequency of >5%; all occurrences of nonsynonymous alleles are shown. (Two SNPs, at positions 2853 and 7229, 586 
had nominal derived allele frequencies over 95%; in both cases, the “ancestral” allele was seen only in a small clade 587 
within the tree, suggesting that the ancestral allele was incorrectly assigned.) We placed mutations at a node such 588 
that the node leads only to samples with the mutation or with no call at that site. Uncertainty in placement occurs 589 
when a sample lacks a base call for the corresponding SNP; in this case, we placed the SNP on the most recent 590 
branch for which we have available data. We also used this ancestral ZIKV state to count the frequency of each type 591 
of substitution over various regions of the ZIKV genome, per number of available bases in each region (Fig. 3d and 592 
Supplementary Table 3). 593 
 594 
We quantified the effect of nonsynonymous SNPs using the original BLOSUM62 scoring matrix for amino acids52, 595 
in which positive scores indicate conservative amino acid changes and negative scores unlikely or extreme 596 
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substitutions. We assessed statistical significance for equality of proportions by χ2 test (Fig. 3c, middle), and for 597 
difference of means by 2-sample t-test with Welch-Satterthwaite approximation of df (Fig. 3c, right). Error bars are 598 
95% confidence intervals derived from binomial distributions (Fig. 3c, left and middle; Fig. 3d) or Student's t-599 
distributions (Fig. 3c, right). 600 
 601 
Maximum likelihood estimation and root-to-tip regression 602 
We generated a maximum likelihood tree using a multiple sequence alignment that included genomes generated in 603 
this study, as well as a selection of other available sequences from the Americas, Southeast Asia, and the Pacific. 604 
The sequences are listed in Supplementary Information. We ran PhyML53 with the GTR substitution model and 4 605 
gamma substitution rate categories; for the tree search operation, we used ‘BEST’ (best of NNI and SPR). In 606 
FigTree v1.4.254, we rooted the tree on the oldest sequence used as input (GenBank accession EU545988.1). 607 
 608 
We used TempEst v1.555, which selects the best-fitting root with a residual mean squared function, to estimate root-609 
to-tip distances. We performed regression in R with the lm function47 of distances on dates. The relationship 610 
between root-to-tip divergence and sample dates (Extended Data Fig. 2) supports the use of a molecular clock 611 
analysis in this study. 612 
 613 
In Supplementary Data, we provide the output of PhyML, as well as the dates and distances used for root-to-tip 614 
regression. 615 
 616 
Molecular clock phylogenetics and ancestral state reconstruction 617 
For molecular clock phylogenetics, we made a multiple sequence alignment from the genomes generated in this 618 
study combined with a selection of other available sequences from the Americas. We did not use sequences from 619 
outside the outbreak in the Americas. Among ZIKV genomes published and publicly available on NCBI GenBank35, 620 
we selected 32 from the Americas that had at least 7000 unambiguous bases, were not labeled as having been 621 
passaged more than once, and had location metadata. We also used 32 genomes from Brazil published in a 622 
companion paper10 that met the same criteria. The sequences are listed in Supplementary Information. 623 
 624 
We used BEAST v1.8.4 to perform molecular clock analyses56. We used sampled tip dates to handle inexact dates57. 625 
Because of sparse data in non-coding regions, we used only the CDS as input. We used the SDR06 substitution 626 
model on the CDS, which uses HKY with gamma site heterogeneity and partitions codons into two partitions 627 
(positions (1+2) and 3)58. To perform model selection, we tested three coalescent tree priors: a constant-size 628 
population, an exponential growth population, and a Bayesian Skyline tree prior (10 groups, piecewise-constant 629 
model)59. For each tree prior, we tested two clock models: a strict clock and an uncorrelated relaxed clock with 630 
lognormal distribution (UCLN)60. In each case, we set the molecular clock rate to use a continuous time Markov 631 
chain rate reference prior61. For all six combinations of models, we performed path sampling (PS) and stepping-632 
stone sampling (SS) to estimate marginal likelihood62,63. We sampled for 100 path steps with a chain length of 1 633 
million, with power posteriors determined from evenly spaced quantiles of a Beta(alpha=0.3; 1.0) distribution. The 634 
Skyline tree prior provided a better fit than the two other (baseline) tree priors (Extended Data Table 2), so we used 635 
this tree prior for all further analyses. Using a constant or exponential tree prior, a relaxed clock provides a better 636 
model fit, as shown by the log Bayes factor when comparing the two clock models. Using a Skyline tree prior, the 637 
log Bayes factor comparing a strict and relaxed clock is smaller than it is using the other tree priors, and it is similar 638 
to the variability between estimated log marginal likelihood from PS and SS methods. We chose to use a relaxed 639 
clock for further analyses, but we also report key findings using a strict clock. 640 
 641 
For the tree and tMRCA estimates in Fig. 2, as well as the clock rate reported in main text, we ran BEAST with 400 642 
million MCMC steps using the SRD06 substitution model, Skyline tree prior, and relaxed clock model. We 643 
extracted clock rate and tMRCA estimates, and their distributions, with Tracer v1.6.0 and identified the maximum 644 
clade credibility (MCC) tree using TreeAnnotator v1.8.2. The reported credible intervals around estimates are 95% 645 
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highest posterior density (HPD) intervals. When reporting substitution rate from a relaxed clock model, we give the 646 
mean rate (mean of the rates of each branch weighted by the time length of the branch). Additionally, for the 647 
tMRCA estimates in Fig. 2c with a strict clock, we ran BEAST with the same specifications (also with 400M steps) 648 
except used a strict clock model. The resulting data are also used in the more comprehensive comparison shown in 649 
Extended Data Fig. 3. 650 
 651 
For the data with an outgroup in Extended Data Fig. 3, we ran BEAST the same as specified above (with strict and 652 
relaxed clock models), except with 100 million steps and with outgroup sequences in the input alignment. The 653 
outgroup sequences were the same as those used to make the maximum likelihood tree (see Supplementary 654 
Information). For the data excluding sample DOM_2016_MA-WGS16-020-SER in Extended Data Fig. 3, we ran 655 
BEAST the same as specified above (with strict and relaxed clocks), except we removed this sample from the input 656 
and ran 100 million steps. 657 
 658 
We used BEAST v1.8.4 to estimate transition and transversion rates with CDS and non-coding regions. The model 659 
was the same as above except that we used the Yang96 substitution model on the CDS, which uses GTR with 660 
gamma site heterogeneity and partitions codons into three partitions64; for the non-coding regions, we used a GTR 661 
substitution model with gamma site heterogeneity and no codon partitioning. There were four partitions in total: one 662 
for each codon position and another for the non-coding region (5' and 3' UTRs combined). We ran this for 200 663 
million steps. At each sampled step of the MCMC, we calculated substitution rates for each partition using the 664 
overall substitution rate, the relative substitution rate of the partition, the relative rates of substitutions in the 665 
partition, and base frequencies. In Extended Data Fig. 4, we plot the means of these rates over the steps; the error 666 
bars shown are 95% HPD intervals of the rates over the steps. 667 
 668 
We used BEAST v1.8.4 to reconstruct ancestral state at the root of the tree using CDS and non-coding regions. The 669 
model was the same as above except that, on the CDS, we used the HKY substitution model with gamma site 670 
heterogeneity and codons partitioned into three partitions (one per codon position). On the non-coding regions we 671 
used the same substitution model without codon partitioning. We ran this for 50 million steps and used 672 
TreeAnnotator v1.8.2 to find the state with the MCC tree. We selected the ancestral state corresponding to this state. 673 
 674 
In all BEAST runs, we discarded the first 10% of states from each run as burn-in. 675 
 676 
In Supplementary Data, we provide BEAST input (XML) and output files. We also provide the sequence of the 677 
reconstructed ancestral state. 678 
 679 
Principal component analysis 680 
We carried out principal component analysis using the R package FactoMineR65. We imputed missing data with the 681 
package missMDA66 and we show the results in Fig. 2d. 682 
 683 
Diagnostic assay assessment 684 
We extracted primer and probe sequences from eight published RT-qPCR assays26–31 and aligned to our ZIKV 685 
genomes using Geneious version 9.1.751. We then tabulated matches and mismatches to the diagnostic sequence for 686 
all outbreak genomes, allowing multiple bases to match where the diagnostic primer and/or probe sequence 687 
contained nucleotide ambiguity codes (Fig. 3e). 688 
 689 
Data availability 690 
Sequence data that support findings of this study are deposited in NCBI GenBank35 under BioProject accession 691 
PRJNA344504. Zika virus genomes have accession numbers KY014295-KY014327 and KY785409-KY785485. 692 
The dengue virus type 1 genome sequenced in this study has accession number KY829115. See Supplementary 693 
Table 1 for a mapping of sample names to accession numbers.  694 
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Extended Data Figures 695 
 696 
Extended Data Figure 1 | Relationship between metadata and sequencing outcome. Analysis of possible 697 
predictors of sequencing outcome: the site where a sample was collected, patient gender, patient age, sample type, 698 
and days between symptom onset and sample collection (“collection interval”). (a) Prediction of whether a sample 699 
passes assembly thresholds by sequencing. Rows show results of likelihood ratio tests on each predictor by omitting 700 
the variable from a full model that contains all predictors. Sample site and patient gender improve model fit, but 701 
sample type and collection interval do not. (b) Proportion of samples that pass assembly thresholds by sequencing, 702 
divided by sample type, across six sample sites. (c) Same as (b), except divided by collection interval. (d) Prediction 703 
of the genome fraction identified, using samples passing assembly thresholds. Rows show results of likelihood ratio 704 
tests, as in (a). Collection interval improves the model, but sample type does not. (e) Sequencing outcome for each 705 
sample, divided by sample type, across six sample sites. (f) Same as (e), except divided by collection interval. 706 
Samples collected 7+ days after symptom onset produced, on average, the fewest unambiguous bases, though these 707 
observations are based on a limited number of data points. While the sample site variable accounts for differences in 708 
cohort composition, the observed effects of gender and collection interval might be due to confounders in composition 709 
that span multiple cohorts. These results illustrate the effect of variables on sequencing outcome for the samples in 710 
this study; they are not indicative of ZIKV titer more generally. Other studies67,68 have analyzed the impact of sample 711 
type and collection interval on ZIKV detection, sometimes with differing results. 712 
 713 
Extended Data Figure 2 | Maximum likelihood tree and root-to-tip regression. (a) Tips are colored by sample 714 
source location. Labeled tips indicate those generated in this study; all other colored tips are other publicly available 715 
genomes from the outbreak in the Americas. Grey tips are samples from ZIKV cases in Southeast Asia and the 716 
Pacific. (b) Linear regression of root-to-tip divergence on dates. The substitution rate for the full tree, indicated by the 717 
slope of the black regression line, is similar to rates of Asian lineage ZIKV estimated by molecular clock analyses12. 718 
The substitution rate for sequences within the Americas outbreak only, indicated by the slope of the green regression 719 
line, is similar to rates estimated by BEAST (1.15x10-3; 95% CI [9.78x10-4, 1.33x10-3]) for this data set. 720 
 721 
Extended Data Figure 3 | Substitution rate and tMRCA distributions. (a) Posterior density of the substitution rate. 722 
Shown with and without the use of sequences (outgroup) from outside the Americas. (b-e) Posterior density of the 723 
date of the most recent common ancestor (MRCA) of sequences in four regions corresponding to those in Fig. 2c. 724 
Shown with and without the use of outgroup sequences. The use of outgroup sequences has little effect on estimates 725 
of these dates. (f) Posterior density of the date of the MRCA of sequences in a clade consisting of samples from the 726 
Caribbean and continental US. Shown with and without the sequence of DOM_2016_MA-WGS16-020-SER, a 727 
sample from the Dominican Republic that has only 3037 unambiguous bases; this is the most ancestral sequence in 728 
the clade and its presence affects the tMRCA. In (a-f), all densities are shown as observed with a relaxed clock model 729 
and with a strict clock model. 730 
 731 
Extended Data Figure 4 | Substitution rates estimated with BEAST. Substitution rates estimated in three codon 732 
positions and non-coding regions (5’ and 3’ UTRs). Transversions are shown in grey and transitions are colored by 733 
transition type. Plotted values show the mean of rates calculated at each sampled Markov chain Monte Carlo 734 
(MCMC) step of a BEAST run. These calculated rates provide additional evidence for the observed high C-to-T and 735 
T-to-C transition rates shown in Fig. 3d. 736 
 737 
Extended Data Figure 5 | cDNA concentration of amplicon primer pools predicts sequencing outcome. cDNA 738 
concentration of amplicon pools (as measured by Agilent 2200 Tapestation) is highly predictive of amplicon 739 
sequencing outcome. On each axis, 1+primer pool concentration is plotted on a log scale. Each point is a technical 740 
replicate of a sample and colors denote observed sequencing outcome of the replicate. If a replicate is predicted to 741 
be passing when at least one primer pool concentration is ≥0.8 ng/µL, then sensitivity=98.71% and 742 
specificity=90.34%. An accurate predictor of sequencing success early in the sample processing workflow can save 743 
resources. 744 
 745 
Extended Data Figure 6 | Evaluating multiple rounds of Zika virus hybrid capture. Genome assembly statistics 746 
of samples prior to hybrid capture (grey), and after one (blue) or two (red) rounds of hybrid capture. 9 individual 747 
18 
libraries (8 unique samples) were sequenced all three ways, had >1 million raw reads in each method, and generated 748 
at least one passing assembly. Raw reads from each method were downsampled to the same number of raw reads 749 
(8.5 million) before genomes were assembled. (a) Percent of the genome identified, as measured by number of 750 
unambiguous bases. (b) Median sequencing depth of ZIKV genomes, taken over the assembled regions. 751 
 752 
Extended Data Table 1 | Viruses other than Zika uncovered by unbiased sequencing. (a) Viral species other 753 
than Zika were found by unbiased sequencing of 38 samples. Column 3: number of reads in a sample belonging to a 754 
species as a raw count and a percent of total reads. Column 4: percent genome assembled based on the number of 755 
unambiguous bases called. We identified cell fusing agent virus (a flavivirus) and deformed wing virus-like genomes 756 
in mosquito pools, and dengue virus type 1, JC polyomavirus, and JC polyomavirus-like genomes in clinical samples. 757 
All assemblies had ≥95% sequence identity to a reference sequence for the listed species, except cell fusing agent 758 
virus in USA_2016_FL-06-MOS (91%) and dengue virus type 1 in BLM_2016_MA-WGS16-006-SER (92%). The 759 
dengue virus type 1 genome showed ≥95% sequence identity to other available isolates of the virus. (b) Contigs 760 
assembled from unbiased sequencing data of 8 mosquito pools. Column 2: number of contigs assembled. Column 3: 761 
number of contigs classified by BLASTN/BLASTX43. Column 4: number of contigs hitting a viral species. Column 5: 762 
number of contigs hitting a viral species with <80% amino acid identity to the best hit. Each column is a subset of the 763 
previous column. Contigs in column 5 are considered to be likely novel. Last row lists counts, after removing duplicate 764 
contigs, for all mosquito pools combined. Supplementary Table 4 lists the unique viral contigs and their best hit. 765 
 766 
Extended Data Table 2 | Model selection for BEAST analyses. (a) Marginal likelihoods calculated with path 767 
sampling (PS) and stepping-stone sampling (SS) for combinations of three coalescent tree priors (constant size 768 
population, exponential growth population, and Skyline) and two clock models (strict clock and uncorrelated relaxed 769 
clock with log-normal distribution). The Bayes factor is calculated against the baseline model, a constant size tree 770 
prior and strict clock. (b) Mean estimates and 95% credible intervals (CI) across evaluated models for the clock rate, 771 
date of tree root, and tMRCAs of the four regions shown in Fig. 2c. Under a Skyline tree prior, the use of strict and 772 
relaxed clock models yields similar estimates. 773 
 774 
Extended Data Table 3 | Within-sample variant validation between and within sequencing methods. (a) For 775 
each method (amplicon sequencing or hybrid capture), fraction of identified variants (≥1%) not identified at ≥1% by 776 
the other method (i.e. unvalidated). “Verified” hybrid capture variants are those passing strand bias and frequency 777 
filters, as described in Methods. (b) For each method, fraction of identified variants unvalidated in a second library. To 778 
pass the strand bias filter, a variant must meet filter criteria in both replicates. 779 
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